布地奈德联合利巴韦林对毛细支气管炎患儿的临床疗效探讨  

Clinical efficacy of budesonide combined with ribavirin in children with bronchiolitis

作　　者：杨其利 YANG Qi-li(Department of Pharmacy,Zaozhuang Hospital,Shandong Health Group,Tengzhou 277500,China)

机构地区：[1]山东健康集团枣庄医院药剂科,277500

出　　处：《中国现代药物应用》2025年第4期1-4,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析布地奈德联合利巴韦林对毛细支气管炎患儿的临床疗效。方法100例毛细支气管炎患儿,按照入院次序不同分为常规组(先入院)、实验组(后入院),每组50例。常规组予以利巴韦林治疗,实验组予以利巴韦林+布地奈德治疗。比较两组治疗效果、临床症状缓解时间及治疗前后炎症因子[C反应蛋白(CRP)、白细胞介素-8(IL-8)、降钙素原(PCT)]、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、血气分析指标[动脉血二氧化碳分压(Pa CO_(2))、动脉血氧分压(Pa O_(2))、血氧饱和度(Sa O_(2))]。结果实验组患儿的治疗总有效率96.00%明显高于常规组的78.00%(P<0.05)。实验组患儿咳嗽、憋喘、肺哮鸣音、发热缓解时间明显短于常规组(P<0.05)。治疗后,实验组患儿CRP、IL-8、PCT水平分别为(3.17±0.33)mg/L、(39.36±8.22)pg/L、(0.40±0.10)ng/ml,低于常规组的(5.10±0.51)mg/L、(46.90±9.42)pg/L、(0.55±0.19)ng/ml(P<0.05)。治疗后,实验组患儿CD4^(+)(41.41±3.00)%、CD4^(+)/CD8^(+)(1.47±0.30)高于常规组的(33.53±2.55)%、(1.19±0.24),CD8^(+)(30.20±2.90)%低于常规组的(35.80±2.20)%(P<0.05)。治疗后,实验组患儿Pa O_(2)(92.05±2.88)mm Hg(1 mm Hg=0.133 k Pa)、Sa O_(2)(97.05±1.00)%高于常规组的(81.66±5.34)mm Hg、(91.22±1.10)%,Pa CO_(2)(35.09±2.40)mm Hg低于常规组的(38.58±3.99)mm Hg(P<0.05)。结论对毛细支气管炎患儿使用利巴韦林联合布地奈德治疗效果显著,能加速患儿临床症状消退,改善炎症反应与免疫情况,建议临床应用。Objective To analyze the clinical efficacy of budesonide combined with ribavirin in children with bronchiolitis.Methods A total of 100 children with bronchiolitis were selected.According to different order of admission,they were divided into conventional group(patients admitted first)and experimental group(patients admitted later),with 50 cases in each group.The conventional group was treated with ribavirin,and the experimental group was treated with ribavirin^(+)budesonide.Both groups were compared in terms of treatment effect,clinical symptom remission time,levels of inflammatory factors[C-reactive protein(CRP),interleukin-8(IL-8),procalcitonin(PCT)]and immune function indexes(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and blood gas analysis indexes[arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial pressure of oxygen(PaO_(2)),and oxygen saturation(SaO_(2))]before and after treatment.Results The total effective rate of 96.00%in the experimental group was significantly higher than 78.00%in the conventional group(P<0.05).The remission time of cough,asthma,pulmonary wheezing sound and fever in the experimental group were shorter than those in the conventional group(P<0.05).After treatment,the levels of CRP,IL-8 and PCT in the experimental group were(3.17±0.33)mg/L,(39.36±8.22)pg/L and(0.40±0.10)ng/ml,which were lower than(5.10±0.51)mg/L,(46.90±9.42)pg/L and(0.55±0.19)ng/ml in the conventional group(P<0.05).After treatment,the experimental group had CD4^(+)of(41.41±3.00)%and CD4^(+)/CD8^(+)of(1.47±0.30),which were higher than(33.53±2.55)%and(1.19±0.24)in the conventional group;the experimental group had lower CD8^(+)of(30.20±2.90)%than(35.80±2.20)%in the conventional group(P<0.05).After treatment,the experimental group had PaO_(2)of(92.05±2.88)mm Hg(1 mm Hg=0.133 kPa)and SaO_(2)of(97.05±1.00)%,which were higher than(81.66±5.34)mm Hg and(91.22±1.10)%in the conventional group;the experimental group had lower PaCO_(2)of(35.09±2.40)mm Hg than(38.58±3.99)mm Hg in the conventional group(P<0.05)

关 键 词：毛细支气管炎 患儿 利巴韦林 布地奈德 疗效 

分 类 号：R725.6[医药卫生—儿科]